Source: Annual Congress 2005 - Inhaler devices: challenges and solutions
Disease area: Airway diseases

Abstract

We compared the release characteristics of two different types of MDPIs, NOV (Formatris^® Novolizer^®) and AER (Foradil^®P Aerolizer^®). We assessed the delivered dose and the aerodynamic particle size distribution of the fine particle dose of formoterol fumarate dihydrate powder for inhalation.
The two devices have significantly different airflow resistances due to their different constructions. These differences in airflow resistance result in different pressure drops for each MDPI at a defined inspiratory flow rate. The release characteristics of both devices were assessed at defined pressure drops to ensure comparability of the results, because the pressure drop is generated by the inspiratory effort of the patient.
For both devices, the results show only a slight dependence of the delivered dose on the pressure drop in the range of 2-5 kPa.
In comparison, the delivered dose through the NOV was consistently higher than that delivered through the AER. The complete release of powder through the device is essential for the correct use of the inhaler by the patient.
The fine particle doses for both the NOV and the AER were comparable and as for almost all breath-actuated dry powder devices slightly dependent on the pressure drop and thus on the corresponding airflow rate.
Thus, more reliable dosing of NOV (Novolizer^®) can be assumed from these in-vitro results.

Rating:

Share or cite this content

Citations should be made in the following way:
B. Bidlingmaier, S. Mueller, B. Fyrnys (Bad Homburg, Germany). Comparison of the release characteristics of formoterol dihydrate powder for inhalation delivered through two different types of multidose dry powder inhalers (MDPI). Eur Respir J 2005; 26: Suppl. 49, 858

Member's Comments

No comment yet.

Related content which might interest you: In-use in vitro performance of formoterol fumarate dihydrate powder for inhalation (6 and 12 µg/dose) delivered from a novel multidose dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003 The genuair® inhaler: a novel multidose dry powder inhaler for the delivery of various types of inhalation powder Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Development of formoterol fumarate dihydrate powder for inhalation (6 µg and 12 µg per dose) delivered through a multi dose dry powder inhaler (MDPI) Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004 Pharmaceutical performances of formoterol delivered from a novel multidose dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001 Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001 Ex-vivo emitted dose characteristics for combination formulations in dry powder inhalers (DPI) Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003 Bronchodilator effect of formoterol delivered by two different dry powder inhalers (DPI) Source: Eur Respir J 2004; 24: Suppl. 48, 310s Year: 2004 Inhalation parameters from an integrated electronic multidose dry powder inhaler (eMDPI) Source: International Congress 2018 – Asthma: clinical screening tools Year: 2018 Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005 Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 260s Year: 2004 Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 Flow-dependent performance of several formoterol dry powder inhalers (DPIs) Source: Eur Respir J 2006; 28: Suppl. 50, 435s Year: 2006 Clinical equivalence of budesonide delivered via two dry powder inhalers Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005 A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 Performance characteristics of a multi dose dry powder inhaler (MDPI) with respect to the use of different deaggregation systems Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004 Development of a powder for inhalation with R,R-Glycopyrrolate as active ingredient for the delivery from a novel multidose dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 471s Year: 2003 Aerodynamic characteristics of dry powder inhaler (DPI) single-dose combination of budesonide with formoterol in vitro study validation Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012 Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005 Comparison of a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) formulation of extra fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in patients with COPD: The TRI-D study. Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020 Variability of budesonide (BUD) fine particle dose (FPD) delivered through two multiple dose dry powder inhalers (MDPI) Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004